5-HT3 SEROTONIN RECEPTOR BLOCKERS FOR INTENSIVE THERAPY OF TRAUMATIC DISEASE IN PATIENTS WITH MULTIPLE TRAUMA

Wiad Lek. 2022;75(11 pt 1):2683-2686. doi: 10.36740/WLek202211123.

Abstract

Objective: The aim: To find the most rational choice of drugs that have anti-emetic effect in patients with polytrauma in acute and early periods.

Patients and methods: Materials and methods: We examined 82 patients with polytrauma, 62 men and 20 women. The age of patients ranged from 19 to 50 years. Patients were divided into the main and control group with 36 and 46 people respectively, who did not differ significantly by sex, age, anthropometric data, the nature and severity of injuries, and the time from injury to admission to hospital.

Results: Results: Full antiemetic effect was achieved in 72.4% of patients, where metoclopramide was used. Сomplete antiemetic effect was achieved in 96.3% of patients, where sturgeon was used. Decrease of peristaltic activity does not increase postoperative intestinal paresis, and also prevents irritable bowel syndrome and diarrhea caused by dysbacteriosis on the background of antibiotic therapy. Anxiolytic effect without sedative effect and impairment of motor coordination, decrease of the somatic and psychopathological symptoms intensity in alcohol-toxic withdrawal syndrome contributes to the correct interpretation of the traumatic disease.

Conclusion: Conclusions: Use of drugs with antiemetic effect is an important part of the complex of traumatic disease treatment in patients with polytrauma. The use of osetron is rational in patients with polytrauma with cranio-abdominal injuries.

Keywords: intensive therapy; multiple trauma; serotonin receptors.

MeSH terms

  • Adult
  • Antiemetics* / therapeutic use
  • Female
  • Humans
  • Male
  • Middle Aged
  • Multiple Trauma* / complications
  • Multiple Trauma* / drug therapy
  • Receptors, Serotonin, 5-HT3
  • Serotonin
  • Serotonin Antagonists
  • Young Adult

Substances

  • Receptors, Serotonin, 5-HT3
  • Antiemetics
  • Serotonin
  • Serotonin Antagonists